Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency.
We analyzed the outcomes of 214 HLA non-identical T-cell-depleted bone marrow transplantations (BMTs), performed in 178 consecutive patients for treatment of severe combined immunodeficiencies (SCID). Patients were treated in 18 European centers between 1981 and March 1995. SCID variants, that is, absence of T and B lymphocytes (B-) or absence of T cells with presence of B lymphocytes (B+) were found to have a major influence on outcome. The disease-free survival was significantly better for patients with B+ SCID (60%) as compared with patients with B- SCID (35%) (P =.002), with a median follow-up of 57 months and 52 months, respectively. Other factors associated with a poor prognosis were the presence of a lung infection before BMT (odds ratio = 2.47 [1.99-2.94]) and the use of monoclonal antibodies for T-cell depletion of the graft (odds ratio = 1.67 [1. 18-2.15]). Additional factors influencing outcome were age at BMT (<6 months) and period during which BMT was performed. Better results were achieved after 1991. Reduced survival of patients with B- SCID was associated with a higher incidence of early deaths from infection, a diminished rate of marrow engraftment, a trend to a higher incidence of chronic graft-versus-host disease, and slower kinetics of T/B immune function development. In both groups of patients, the use of busulfan (8 mg/kg total dose) and cyclophosphamide (200 mg/kg total dose) as a conditioning regimen provided the best cure rate (74% for patients with B+ SCID and 43% for patients with B- SCID, respectively), although results were not statistically significantly different from other regimens. This retrospective analysis should lead to the design of adapted measures to the performance of HLA non-identical BMT in patients with distinct SCID conditions.
Bertrand
Y
Y
Unité d'Immunologie et d'Hématologie Pédiatriques, Département de Pédiatrie, Hôpital Necker-Enfants Malades; Paris, France.
Landais
P
P
Friedrich
W
W
Gerritsen
B
B
Morgan
G
G
Fasth
A
A
Cavazzana-Calvo
M
M
Porta
F
F
Cant
A
A
Espanol
T
T
Müller
S
S
Veys
P
P
Vossen
J
J
Haddad
E
E
Fischer
A
A
D000367:Age Factors; D001402:B-Lymphocytes / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D008297:Male; D016017:Odds Ratio; D010641:Phenotype; D011379:Prognosis; D012141:Respiratory Tract Infections / Q000150:complications; D012189:Retrospective Studies; D016511:Severe Combined Immunodeficiency / Q000150:complications / Q000235:genetics / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D014181:Transplantation Immunology; D016896:Treatment Outcome